| Releuko |
761082 |
001 |
351(k) Biosimilar |
filgrastim-ayow |
Injection |
Intravenous, Subcutaneous |
300MCG/ML |
Single-Dose Vial |
2022/02/25
|
Kashiv BioSciences, LLC |
Rx |
Licensed |
filgrastim |
Neupogen |
| Releuko |
761082 |
002 |
351(k) Biosimilar |
filgrastim-ayow |
Injection |
Intravenous, Subcutaneous |
480MCG/1.6ML |
Single-Dose Vial |
2022/02/25
|
Kashiv BioSciences, LLC |
Rx |
Licensed |
filgrastim |
Neupogen |
| Releuko |
761082 |
003 |
351(k) Biosimilar |
filgrastim-ayow |
Injection |
Subcutaneous |
300MCG/0.5ML |
Pre-Filled Syringe |
2022/02/25
|
Kashiv BioSciences, LLC |
Rx |
Licensed |
filgrastim |
Neupogen |
| Releuko |
761082 |
004 |
351(k) Biosimilar |
filgrastim-ayow |
Injection |
Subcutaneous |
480MCG/0.8ML |
Pre-Filled Syringe |
2022/02/25
|
Kashiv BioSciences, LLC |
Rx |
Licensed |
filgrastim |
Neupogen |
| Takhzyro |
761090 |
002 |
351(a) |
lanadelumab-flyo |
Injection |
Subcutaneous |
300MG/2ML (150MG/ML) |
Pre-Filled Syringe |
2022/02/08
|
Takeda Pharmaceuticals U.S.A., Inc. |
Rx |
Licensed |
N/A |
N/A |
| Enjaymo |
761164 |
001 |
351(a) |
sutimlimab-jome |
Injection |
Intravenous |
1,100MG/22ML (50MG/ML) |
Single-Dose Vial |
2022/02/04
|
Bioverativ Therapeutics, Inc. |
Rx |
Licensed |
N/A |
N/A |
| Spikevax |
125752 |
001 |
351(a) |
COVID-19 Vaccine, mRNA |
Injection |
Intramuscular |
100UG |
Multi-Dose Vial |
2022/01/31
|
ModernaTX, Inc. |
Disc |
Licensed |
N/A |
N/A |
| Vabysmo |
761235 |
001 |
351(a) |
faricimab-svoa |
Injection |
Intravitreal |
6MG/0.05ML (120MG/ML) |
Single-Dose Vial |
2022/01/28
|
Genentech, Inc. |
Rx |
Licensed |
N/A |
N/A |
| Kimmtrak |
761228 |
001 |
351(a) |
tebentafusp-tebn |
Injection |
Intravenous |
100MCG/0.5ML |
Single-Dose Vial |
2022/01/25
|
Immunocore Limited |
Rx |
Licensed |
N/A |
N/A |
| Nucala |
125526 |
004 |
351(a) |
mepolizumab |
Injection |
Subcutaneous |
40MG/0.4ML |
Pre-Filled Syringe |
2022/01/22
|
GlaxoSmithKline LLC |
Rx |
Licensed |
N/A |
N/A |
| Nucala |
761122 |
004 |
351(a) |
mepolizumab |
Injection |
Subcutaneous |
40MG/0.4ML |
Pre-Filled Syringe |
2022/01/22
|
GlaxoSmithKline LLC |
Rx |
Licensed |
N/A |
N/A |
| Adbry |
761180 |
001 |
351(a) |
tralokinumab-ldrm |
Injection |
Subcutaneous |
150MG/ML |
Pre-Filled Syringe |
2021/12/27
|
LEO Pharma A/S |
Rx |
Licensed |
N/A |
N/A |
| Vyvgart |
761195 |
001 |
351(a) |
efgartigimod alfa-fcab |
Injection |
Intravenous |
400MG/20ML (20MG/ML) |
Single-Dose Vial |
2021/12/17
|
Argenx BV |
Rx |
Licensed |
N/A |
N/A |
| Rezvoglar |
761215 |
001 |
351(k) Interchangeable |
insulin glargine-aglr |
Injection |
Subcutaneous |
300UNITS/3ML (100UNITS/ML) |
Autoinjector |
2021/12/17
|
Eli Lilly and Company |
Rx |
Licensed |
insulin glargine |
Lantus |
| Yusimry |
761216 |
001 |
351(k) Biosimilar |
adalimumab-aqvh |
Injection |
Subcutaneous |
40MG/0.8ML |
Pre-Filled Syringe |
2021/12/17
|
Hong Kong King-Friend Industrial Company Limited |
Rx |
Licensed |
adalimumab |
Humira |
| Tezspire |
761224 |
001 |
351(a) |
tezepelumab-ekko |
Injection |
Subcutaneous |
210MG/1.91ML (110MG/ML) |
Single-Dose Vial |
2021/12/17
|
AstraZeneca AB |
Rx |
Licensed |
N/A |
N/A |
| Tezspire |
761224 |
002 |
351(a) |
tezepelumab-ekko |
Injection |
Subcutaneous |
210MG/1.91ML (110MG/ML) |
Pre-Filled Syringe |
2021/12/17
|
AstraZeneca AB |
Rx |
Licensed |
N/A |
N/A |
| Nuwiq |
125555 |
008 |
351(a) |
Antihemophilic Factor (Recombinant) |
For Injection |
Intravenous |
1500IU |
Single-Dose Vial |
2021/12/07
|
Octapharma Pharmazeutika Produktionsges.m.b.H. |
Rx |
Licensed |
|
N/A |
| Prehevbrio |
125737 |
001 |
351(a) |
Hepatitis B Vaccine (Recombinant) |
For Injection |
Intramuscular |
10UG/ML |
Single-Dose Vial |
2021/11/30
|
VBI Vaccines (Delaware), Inc. |
Disc |
Licensed |
N/A |
N/A |
| Besremi |
761166 |
001 |
351(a) |
ropeginterferon alfa-2b-njft |
Injection |
Subcutaneous |
500MCG/ML |
Pre-Filled Syringe |
2021/11/12
|
PharmaEssentia Corporation |
Rx |
Licensed |
N/A |
N/A |